Abbott and Neurocrine Biosciences have entered into a collaboration to develop and commercialize elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase ...

Shandong Luye Pharmaceutical Co. Ltd. has described gonadotropin-releasing hormone receptor (GNRHR) antagonists reported to be useful for the treatment of acne, cancer, dysmenorrhea, endometriosis, ...

CESSATION of gonadotropin-releasing hormone antagonist (GnRH-ant) on trigger day in the GnRH-ant protocol improves the ...

whether using an agonist or an antagonist protocol, the trigger used is human chorionic gonadotropin (hCG), which shares a common subunit with LH and thus acts as a surrogate LH surge. The ...

Researchers say they have identified several factors that may be associated with inadequate ovarian function suppression among premenopausal breast cancer patients receiving endocrine therapy and a ...